Intellia Therapeutics (NTLA) Misses Q2 EPS by 38c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street slides as AI cash burn worries spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil prices set for fourth straight monthly gains as tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts NTLA Hot Sheet
Join SI Premium – FREE
Intellia Therapeutics (NASDAQ: NTLA) reported Q2 EPS of ($1.01), $0.38 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $6.6 million versus the consensus estimate of $11.89 million.
For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel on FedEx Freight (FDXF): 'Enters Its Post-Breakup Era - Time to Hit the Gym and Focus on Itself'
- SanDisk stock tumbles as Kioxia warns on NAND price surge
- Qualcomm shares fall on Intel warning and legal concerns
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
